2. Search Result
Search Result
Results for "

(YTH) domain-containing family proteins (YTHDF)

" in MedChemExpress (MCE) Product Catalog:

821

Inhibitors & Agonists

13

Screening Libraries

12

Fluorescent Dye

26

Biochemical Assay Reagents

100

Peptides

11

Inhibitory Antibodies

121

Natural
Products

611

Recombinant Proteins

27

Isotope-Labeled Compounds

150

Antibodies

4

Click Chemistry

13

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W017132
    2,4-PDCA

    		Histone Demethylase Cancer
    2,4-PDCA (2,4 pyridine dicarboxylic acid) is a broad-spectrum inhibitor of 2OG oxygenase, including JmjC domain-containing family of histone demethylases (JHDMs). 2,4-PDCA is a target chemical in the field of bio-based plastics .
    2,4-PDCA
  • HY-119254
    BAY-850
    4 Publications Verification

    		 Epigenetic Reader Domain Metabolic Disease
    BAY-850 is a potent and isoform selective ATPase family AAA domain-containing protein 2 (ATAD2) inhibitor, with an IC50 of 166 nM.
    BAY-850
  • HY-168610
    YTH-IN-1

    		Epigenetic Reader Domain YTHDF Cancer
    YTH-IN-1 (compound N-7) is a pan-YTH domain inhibitor with the IC50 values of 39 μM, 34 μM, 35 μM, 48 μM and 30 μM for human YTH YTHDF1, YTH YTHDF2, YTH YTHDF3, YTH YTHDC1, and YTH YTHDC2, respectively .
    YTH-IN-1
  • HY-173008
    YTHDF2-IN-1

    		Apoptosis YTHDF Cancer
    YTHDF2-IN-1 (Compound CK-75) is the inhibitor for YT521-B homology domain family 2 YTHDF2 (Kd=26.2 μM), that blocks the interaction between YTHDF2 and m6A RNA. YTHDF2-IN-1 inhibits the colony formation of JAR cells, exhibits antiproliferative activity in a variety of cancer cells (IC50 in micromolar levels), arrests the cell cycle at G0/G1 phase, induces apoptosis in K562 .
    YTHDF2-IN-1
  • HY-N3561
    Cedrelone

    		Apoptosis Cancer
    Cedrelone, a limonoid, is a Phenazine biosynthesis-like domain-containing protein (PBLD) activator. Cedrelone induces cancer cell apoptosis, and possess antitumor effects .
    Cedrelone
  • HY-RS15939
    YTHDF3 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) YTHDF Others

    YTHDF3 Human Pre-designed siRNA Set A contains three designed siRNAs for YTHDF3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    YTHDF3 Human Pre-designed siRNA Set A
    YTHDF3 Human Pre-designed siRNA Set A
  • HY-RS15937
    YTHDF1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) YTHDF Others

    YTHDF1 Human Pre-designed siRNA Set A contains three designed siRNAs for YTHDF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    YTHDF1 Human Pre-designed siRNA Set A
    YTHDF1 Human Pre-designed siRNA Set A
  • HY-RS23691
    Ythdf1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others
    Ythdf1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ythdf1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Ythdf1 Rat Pre-designed siRNA Set A
    Ythdf1 Rat Pre-designed siRNA Set A
  • HY-RS17237
    Ythdf1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA)
    Ythdf1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ythdf1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Ythdf1 Mouse Pre-designed siRNA Set A
    Ythdf1 Mouse Pre-designed siRNA Set A
  • HY-RS15938
    YTHDF2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) YTHDF Others

    YTHDF2 Human Pre-designed siRNA Set A contains three designed siRNAs for YTHDF2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    YTHDF2 Human Pre-designed siRNA Set A
    YTHDF2 Human Pre-designed siRNA Set A
  • HY-RS26325
    Ythdf3 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others
    Ythdf3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ythdf3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Ythdf3 Rat Pre-designed siRNA Set A
    Ythdf3 Rat Pre-designed siRNA Set A
  • HY-RS19828
    Ythdf3 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others
    Ythdf3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ythdf3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Ythdf3 Mouse Pre-designed siRNA Set A
    Ythdf3 Mouse Pre-designed siRNA Set A
  • HY-RS23390
    Ythdf2 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others
    Ythdf2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ythdf2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Ythdf2 Rat Pre-designed siRNA Set A
    Ythdf2 Rat Pre-designed siRNA Set A
  • HY-RS16947
    Ythdf2 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA)
    Ythdf2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ythdf2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Ythdf2 Mouse Pre-designed siRNA Set A
    Ythdf2 Mouse Pre-designed siRNA Set A
  • HY-164607
    YL-5092

    		DNA/RNA Synthesis Cancer
    YL-5092 is an inhibitor for YT521-B homology (YTH) domain-containing protein 1 (YTHDC1). YL-5092 inhibits acute myeloid leukemia cell with IC50 of 0.28-2.87 μM. YL-5092 exhibits antitumor efficacy in MOLM-13 or U937 xenograft mice .
    YL-5092
  • HY-158774
    TG2-179-1

    		Apoptosis Cancer
    TG2-179-1 is a potent BAP1 inhibitor. TG2-179-1 inhibits the domain-containing deubiquitinase (DUB) activity of BAP1 by covalently binding to its active site. TG2-179-1 exerts cytotoxic activity, leading to defective replication and increased apoptosis. TG2-179-1 has the potential for colon cancer research .
    TG2-179-1
  • HY-119254A
    trans-BAY-850

    		Epigenetic Reader Domain Metabolic Disease
    trans-BAY-850 is the trans isomer of BAY-850 (HY-119254). BAY-850 is a potent and isoform selective ATPase family AAA domain-containing protein 2 (ATAD2) inhibitor, with an IC50 of 166 nM.
    trans-BAY-850
  • HY-18685
    CPDA

    		Phosphatase Metabolic Disease
    CPDA is a novel potent SH2 domain-containing inositol phosphatase 2 (SHIP2) inhibitor.
    CPDA
  • HY-122198
    ML367

    		Checkpoint Kinase (Chk) Cancer
    ML367 is a potent inhibitor of ATPase family AAA domain-containing protein 5 (ATAD5) stabilization, acts as a probe molecule that has low micromolar inhibitory activity. ML367 blocks DNA repair pathways, suppresses general DNA damage responses including RPA32-phosphorylation and CHK1-phosphorylation in response to UV irradiation .
    ML367
  • HY-101628
    VEGFR-2-IN-9

    KDR-in-4

    		 VEGFR Cardiovascular Disease
    VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insert domain-containing receptor (KDR/VEGFR2) inhibitor with an IC50 of 7 nM.
    VEGFR-2-IN-9
  • HY-19776
    3α-Aminocholestane
    5 Publications Verification

    		 Phosphatase Cancer
    3α-Aminocholestane is a selective SH2 domain-containing inositol-5′-phosphatase 1 (SHIP1) inhibitor with an IC50 of ~2.5 μM.
    3α-Aminocholestane
  • HY-159656
    PNPLA3 modifier 1

    		Lipase Others
    PNPLA3 modifier 1 (compound 10) is a Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifier, with a geometric mean EC50 of 4.9 nM .
    PNPLA3 modifier 1
  • HY-129121
    ML-​226

    		MAGL Neurological Disease
    ML226 is a potent α/β hydrolase domain-containing protein 11 (ABHD11) inhibitor in vitro and in situ with IC50s of 15 and 0.68 nM, respectively .
    ML-​226
  • HY-100871
    WT-161
    5+ Cited Publications

    		 Beta-lactamase HDAC Apoptosis Cancer
    WT-161 is a potent and selective HDAC6 inhibitor with an IC50 of 0.40 nM . WT-161 also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) .
    WT-161
  • HY-N0170
    Indole-3-carbinol
    5+ Cited Publications

    Indole-3-methanol

    		 NF-κB Aryl Hydrocarbon Receptor E1/E2/E3 Enzyme Endogenous Metabolite Cancer
    Indole-3-carbinol (I3C) inhibits NF-κB activity and also is an Aryl hydrocarbon receptor (AhR) agonist, and an inhibitor of WWP1 (WW domain-containing ubiquitin E3 ligase 1).
    Indole-3-carbinol
  • HY-13428
    Tubacin
    10+ Cited Publications

    		 Beta-lactamase HDAC Virus Protease Cancer
    Tubacin is a potent and selective inhibitor of HDAC6, with an IC50 value of 4 nM and approximately 350-fold selectivity over HDAC1. Tubacin also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2).
    Tubacin
  • HY-19328
    ACY-775
    2 Publications Verification

    		 HDAC Cardiovascular Disease Neurological Disease
    ACY-775 is a potent and selective inhibitor of the of histone deacetylase 6 (HDAC6) with an IC50 of 7.5 nM . ACY775 also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) .
    ACY-775
  • HY-10990
    Abexinostat
    5+ Cited Publications

    CRA 024781; PCI-24781

    		 HDAC Cancer
    Abexinostat (CRA 024781) is a novel pan-HDAC inhibitor mostly targeting HDAC1 with Ki of 7 nM. Abexinostat also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC50 below 10 nM .
    Abexinostat
  • HY-13322
    Pracinostat
    5+ Cited Publications

    SB939

    		 Beta-lactamase HDAC Apoptosis Cancer
    Pracinostat is a potent histone deacetylase (HDAC) inhibitor, with IC50s of 40-140 nM, used for cancer research. Pracinostat also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC50 below 10 nM .
    Pracinostat
  • HY-105246
    Pracinostat dihydrochloride

    		Beta-lactamase HDAC Apoptosis Cancer
    Pracinostat dihydrochloride is a potent histone deacetylase (HDAC) inhibitor, with IC50s of 40-140 nM, used for cancer research. Pracinostat dihydrochloride also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC50 below 10 nM .
    Pracinostat dihydrochloride
  • HY-P1610
    Asudemotide

    		PD-1/PD-L1 Cancer
    Asudemotide (S-588410) is a peptide of human DEP domain-containing protein 1A. Asudemotide is an immunostimulant. Asudemotide has a sequence of H-Glu-Tyr-Tyr-Glu-Leu-Phe-Val-Asn-Ile-OH. Asudemotide induces a tumor immune response in esophageal cancer. .
    Asudemotide
  • HY-N12613
    Sydowimide A

    		Phosphatase Inflammation/Immunology
    Sydowimide A is a potent inhibitor of Src homology region 2 domain-containing phosphatase-1 (SHP1), T-cell protein tyrosine phosphatase (TCPTP) and leukocyte common antigen (CD45), with IC50 values of 1.5, 2.4 and 18.83 μM, respectively .
    Sydowimide A
  • HY-153608
    JHDM-IN-1

    		Histone Demethylase Cancer
    JHDM-IN-1 (Compound 1) is a Jumonji C domain-containing HDMs (JHDM) inhibitor with IC50s of 3.4, 4.3, 5.9, 10 and 43 μM against JMJD2C, JMJD2A, JMJD2E, PHF8 and JMJD3, respectively .
    JHDM-IN-1
  • HY-13271A
    Tubastatin A
    25+ Cited Publications

    		 Beta-lactamase HDAC Autophagy Apoptosis Cancer
    Tubastatin A is a potent and selective HDAC6 inhibitor with an IC50 of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A also inhibits HDAC10 and metallo-β-lactamase domain-containing protein 2 (MBLAC2).
    Tubastatin A
  • HY-138623
    GSK789

    		Epigenetic Reader Domain Inflammation/Immunology Cancer
    GSK789 is an effective, cell-permeable, and highly selective inhibitor of the BET family first bromodomain (BD1), with antitumor and immunomodulatory effects
    GSK789
  • HY-13271
    Tubastatin A Hydrochloride
    25+ Cited Publications

    Tubastatin A HCl; TSA HCl

    		 Beta-lactamase HDAC Autophagy Apoptosis Cancer
    Tubastatin A Hydrochloride (Tubastatin A HCl) is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A Hydrochloride also inhibits HDAC10 and metallo-β-lactamase domain-containing protein 2 (MBLAC2).
    Tubastatin A Hydrochloride
  • HY-161727
    P2Y14R antagonist 1

    		P2Y Receptor NOD-like Receptor (NLR) Inflammation/Immunology
    P2Y14R antagonist 1 (compound I-17) is a selective P2Y14R antagonist with an IC50 of 0.6 nM. It exhibits potent P2Y14R antagonistic activity, both in vitro and in vivo efficacy, and favorable pharmacokinetic profiles. P2Y14R antagonist 1 reduces the release of inflammatory factors and cell pyroptosis through the NOD-like receptor family pyrin domain-containing 3 (NLRP3)/gasdermin D (GSDMD) signaling pathway. P2Y14R antagonist 1 holds promise for research in the field of acute gouty arthritis .
    P2Y14R antagonist 1
  • HY-124418
    SBI-477
    1 Publications Verification

    		 Fluorescent Dye Metabolic Disease
    SBI-477 is a chemical probe stimulated insulin signaling by deactivating the transcription factor MondoA, leading to reduced expression of the insulin pathway suppressors thioredoxin-interacting protein (TXNIP) and arrestin domain–containing 4 (ARRDC4). SBI-477 coordinately inhibits triacylglyceride (TAG) synthesis and enhances basal glucose uptake in human skeletal myocytes .
    SBI-477
  • HY-139782
    SKLB325
    1 Publications Verification

    		 Histone Demethylase Apoptosis Cancer
    SKLB325 is a Jumonji domain-containing 6 (JMJD6) inhibitor with a binding affinity (KD) value of 0.755 μM, and the IC50 value of 0.7797 μM. SKLB325 exhibits antitumor effects on ovarian cancer in vivo and in vitro. SKLB325 induces apoptosis . SKLB325 exhibits remarkable antitumor efficacy in renal cell carcinoma (RCC) .
    SKLB325
  • HY-N4081
    Dracorhodin

    		Others Cardiovascular Disease
    Dracorhodin, the main component in sanguis draconis, is a flavylium compound belonging to the anthocyanin family. Dracorhodin can induce vasodilatation .
    Dracorhodin
  • HY-157251A
    UNC8153

    		Histone Methyltransferase Cancer
    UNC8153 is a potent and selective nuclear receptor-binding SET domain-containing 2 (NSD2)-targeted degrader with a Kd of 24 nM. UNC8153 reduces the cellular levels of both NSD2 protein and the H3K36me2 chromatin mark. UNC8153 contains a simple warhead that confers proteasome-dependent degradation of NSD2 .
    UNC8153
  • HY-100824
    PP2 Analog

    		Src Cancer
    PP2 Analog (compound 3) is a ATP-competitive Src family kinases inhibitor with the IC50 values of 0.22, 0.15, 2.68, and 7 aganist of lck (64-509), src , kdr, and tie-2 .
    PP2 Analog
  • HY-13271B
    Tubastatin A TFA

    TSA TFA

    		 HDAC Autophagy Apoptosis Cancer
    Tubastatin A (TSA) TFA is a potent and selective?HDAC6?inhibitor with?IC50?of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A TFA also inhibits HDAC10 and metallo-β-lactamase domain-containing protein?2 (MBLAC2).
    Tubastatin A TFA
  • HY-N15264
    Azaspirene

    (-)-Azaspirene

    		 VEGFR Raf Cancer
    Azaspirene ((-)-Azaspirene) is an angiogenesis and Raf-1 activation inhibitor isolated from the fungus Neosartorya sp. Azaspirene inhibits vascular endothelial growth factor (VEGF)-induced human umbilical vein endothelial cell (HUVEC) migration and Raf-1 activation, but has no effect on the activation of kinase insert domain-containing receptor/fetal liver kinase 1 (VEGF receptor 2) .
    Azaspirene
  • HY-172432
    Plodicitinib

    		Tyrosinase Inflammation/Immunology
    Plodicitinib is a Janus tyrosine kinase 3/TEC family kinase inhibitor with anti-inflammatory activity .
    Plodicitinib
  • HY-N0086R
    N6-Methyladenosine (Standard)

    		Influenza Virus Endogenous Metabolite Infection
    N6-Methyladenosine (Standard) is the analytical standard of N6-Methyladenosine. This product is intended for research and analytical applications. N6-Methyladenosine is the most prevalent internal (non-cap) modification present in the messenger RNA (mRNA) of all higher eukaryotes. N6-Methyladenosine can modifies viral RNAs and has antiviral activities. In Vitro: N6-methyladenosine (m6A) is selectively recognized by the human YTH domain family 2 (YTHDF2) protein to regulate mRNA degradation. N6-methyladenosine (m6A), a prevalent internal modification in the messenger RNA of all eukaryotes, is post-transcriptionally installed by m6A methyltransferase (e.g., MT-A70) within the consensus sequence of G(m6A)C (70%) or A(m6A)C (30%). N6-methyladenosine (m6A)-containing RNAs are greatly enriched in the YTHDF-bound portion and diminished in the flow-through portion . N6-methyladenosine (m6A), the most abundant internal RNA modification, functions in diverse biological processes, including regulation of embryonic stem cell self-renewal and differentiation. N6-methyladenosine (m6A) is a large protein complex, consisting in part of methyltransferase-like 3 (METTL3) and methyltransferase-like 14 (METTL14) catalytic subunits .
    N6-Methyladenosine (Standard)
  • HY-157251
    UNC8153 TFA

    		Histone Methyltransferase Cancer
    UNC8153 TFA is a potent and selective nuclear receptor-binding SET domain-containing 2 (NSD2)-targeted degrader with a Kd of 24 nM. UNC8153 TFA reduces the cellular levels of both NSD2 protein and the H3K36me2 chromatin mark. UNC8153 TFA contains a simple warhead that confers proteasome-dependent degradation of NSD2 .
    UNC8153 TFA
  • HY-125859B
    Lactoperoxidase, bovine milk

    		Bacterial Infection
    Lactoperoxidase, bovine milk is an antimicrobial protein that belongs to the mammalian heme peroxidase family. Lactoperoxidase, bovine milk uses H2O2 to catalyze the oxidation of its preferred halide substrates including I −, Br −, F −, or the pseudohalide SCN − .
    Lactoperoxidase, bovine milk
  • HY-148187
    NLRP3-IN-11

    		NOD-like Receptor (NLR) Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology
    NLRP3-IN-11 is a NLR family pyrin domain containing 3 (NLRP3) proteins inhibitor. NLRP3-IN-11 has biological activity for NLRP3 with an IC50 value of <0.3 μM. NLRP3-IN-11 can be used for the researh of inflammatory and degenerative diseases including NASH, atherosclerosis and other cardiovascular diseases, Alzheimer's disease, Parkinson's disease, diabetes, gout, and numerous other autoinflammatory diseases .
    NLRP3-IN-11
  • HY-169937
    (R)-SR-C-107

    		Epigenetic Reader Domain Cancer
    (R)-SR-C-107 is an orally available inhibitor of ENL (YEAST domain-containing protein) designed to target acute myeloid leukemia (AML). (R)-SR-C-107 targets ENL with IC50 and KD of 40 nM and 144 nM, respectively. (R)-SR-C-107 demonstrates in vivo efficacy in a xenograft mouse model of AML, with a tumor regression rate of 45% at a dose of 200 mg/kg (PO; QD) .
    (R)-SR-C-107

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: